Matthew S. Davids, MD, on Younger Patients With CLL: Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy

January 25, 2022 By The ASCO Post Staff

Matthew S. Davids, MD, of Dana-Farber Cancer Institute, discusses phase II results from a multicenter study that showed the efficacy of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in younger, fit patients with chronic lymphocytic leukemia who desire the possibility of a functional cure with time-limited therapy (Abstract 640).

Related Content